[Therapeutic use of amezinium methylsulfate--a new, long acting, sympathomimetic--in paraspinal conduction anesthesia].
Cardiovascular effects of the new sympathomimetic ameziniummetilsulphate were investigated in 25 patients compared with a control group (n = 25). During spinal/epidural anaesthesia 5 mg amezinium was given i.v. if blood pressure dropped greater than 20 mmHg. from starting-point. A significant recovery of blood pressure (epidural anaesthesia: syst 21%, diast 9%; spinal anaesthesia: syst 13%, diast 6.6%) and a decrease in heart rate (6.8% resp. 4,5%) were thought due to peripheral vasoconstriction. Amezinium proved a stimulating drug for alpha- and beta 1-receptors by stabilising the systemic blood pressure in spinal/epidural anaesthesia.
D000767:Anesthesia, Epidural; D000775:Anesthesia, Spinal; D001794:Blood Pressure / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D011724:Pyridazines / Q000627:therapeutic use*; D013566:Sympathomimetics / Q000627:therapeutic use*
D011724:Pyridazines; D013566:Sympathomimetics; C027784:amezinium
Therapeutische Anwendung von Ameziniummetilsulfat--einem neuen, langwirkenden Sympathikomimetikum--bei rückenmarksnaher Leitungsanästhesie.